Everpar Advisors LLC Buys New Shares in Zoetis Inc. (NYSE:ZTS)

Everpar Advisors LLC bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,499 shares of the company’s stock, valued at approximately $296,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Blue Bell Private Wealth Management LLC raised its holdings in shares of Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after acquiring an additional 89 shares during the period. Independence Bank of Kentucky increased its stake in Zoetis by 371.4% in the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after buying an additional 130 shares during the period. Ramirez Asset Management Inc. acquired a new position in Zoetis in the 3rd quarter valued at approximately $35,000. First Financial Corp IN increased its stake in Zoetis by 57.2% in the 4th quarter. First Financial Corp IN now owns 217 shares of the company’s stock valued at $43,000 after buying an additional 79 shares during the period. Finally, Bogart Wealth LLC increased its stake in Zoetis by 188.9% in the 3rd quarter. Bogart Wealth LLC now owns 260 shares of the company’s stock valued at $45,000 after buying an additional 170 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. HSBC dropped their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday. The Goldman Sachs Group dropped their price objective on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research note on Monday. Stifel Nicolaus dropped their price target on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. Piper Sandler restated an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Finally, StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $211.75.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 2,209 shares of company stock valued at $371,293 in the last ninety days. Company insiders own 0.16% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE ZTS traded down $3.53 during trading hours on Wednesday, hitting $164.92. 4,669,191 shares of the stock were exchanged, compared to its average volume of 3,195,939. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94. The company’s 50 day moving average is $167.64 and its 200 day moving average is $178.93. The firm has a market capitalization of $75.25 billion, a P/E ratio of 31.78, a P/E/G ratio of 2.57 and a beta of 0.86. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The firm had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same period in the prior year, the firm earned $1.31 EPS. The business’s revenue was up 9.5% on a year-over-year basis. On average, research analysts expect that Zoetis Inc. will post 5.77 EPS for the current year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.